North Texas Tollway Authority's Revenue Bonds Rated 'A+' Jan 05

  • ID: 2024044
  • January 2005
  • Region: Texas
  • Standard & Poors
1 of 3


  • North Texas Tollway Auth
  • MORE

NEW YORK (Standard & Poor's) Jan. 25, 2005--Standard & Poor's Ratings Services assigned its 'A+' rating to North Texas Tollway Authority's (NTTA, or the authority) $236.9 million revenue bonds series 2005A and $79.0 million variable-rate revenue bonds series 2005B. At the same time, Standard & Poor's affirmed its 'A+' rating on NTTA's $1.1 billion of revenue bonds outstanding. The rating is based on NTTA's demonstrated ability to build and support its planned expansion projects while maintaining projected solid debt service coverage, as well as the continued strong growth of the system. The outlook is stable based on the expectation that the NTTA will continue to balance the needs of the existing system expansion projects required to address regional growth while...

Companies mentioned in this report are:
- North Texas Tollway Auth

Action: Affirmed
Action: New Rating
Action: Outlook: Stable

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- North Texas Tollway Auth

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.